HomeCompareRYMSX vs JNJ

RYMSX vs JNJ: Dividend Comparison 2026

RYMSX yields 9.77% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RYMSX wins by $18.2K in total portfolio value
10 years
RYMSX
RYMSX
● Live price
9.77%
Share price
$23.66
Annual div
$2.31
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.2K
Annual income
$1,806.91
Full RYMSX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — RYMSX vs JNJ

📍 RYMSX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRYMSXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RYMSX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RYMSX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RYMSX
Annual income on $10K today (after 15% tax)
$830.68/yr
After 10yr DRIP, annual income (after tax)
$1,535.87/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, RYMSX beats the other by $832.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RYMSX + JNJ for your $10,000?

RYMSX: 50%JNJ: 50%
100% JNJ50/50100% RYMSX
Portfolio after 10yr
$29.1K
Annual income
$1,317.35/yr
Blended yield
4.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RYMSX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RYMSX buys
0
JNJ buys
0
No recent congressional trades found for RYMSX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRYMSXJNJ
Forward yield9.77%3.36%
Annual dividend / share$2.31$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$38.2K$20.0K
Annual income after 10y$1,806.91$827.78
Total dividends collected$13.9K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RYMSX vs JNJ ($10,000, DRIP)

YearRYMSX PortfolioRYMSX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,677$977.27$10,676$355.77+$1.0KRYMSX
2$13,561$1,066.53$11,407$389.39+$2.2KRYMSX
3$15,668$1,157.57$12,198$426.53+$3.5KRYMSX
4$18,015$1,249.91$13,056$467.62+$5.0KRYMSX
5$20,619$1,343.10$13,987$513.12+$6.6KRYMSX
6$23,499$1,436.69$14,998$563.56+$8.5KRYMSX
7$26,674$1,530.25$16,098$619.52+$10.6KRYMSX
8$30,165$1,623.38$17,295$681.69+$12.9KRYMSX
9$33,992$1,715.71$18,599$750.82+$15.4KRYMSX
10$38,178$1,806.91$20,022$827.78+$18.2KRYMSX

RYMSX vs JNJ: Complete Analysis 2026

RYMSXStock

The fund pursues multiple investment styles or mandates that correspond to investment strategies widely employed by hedge funds. The advisor's decision to allocate assets to a particular strategy or strategies is based on a proprietary evaluation of the strategy's risk and return characteristics. It also may invest up to 25% of its total assets in a wholly-owned and controlled Cayman Islands subsidiary.

Full RYMSX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this RYMSX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RYMSX vs SCHDRYMSX vs JEPIRYMSX vs ORYMSX vs KORYMSX vs MAINRYMSX vs ABBVRYMSX vs MRKRYMSX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.